News Taiho snaps up ADC partner Araris for up to $1.14bn Taiho has reached a deal to buy Swiss biotech Araris, around 18 months after they started collaborating on antibody-drug conjugates for cancer.
News Roche builds in obesity with $5.3bn Zealand licensing deal Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma.
News J&J abandons work with Genmab on Darzalex successor Genmab is facing increased pressure to deliver on its in-house pipeline after Johnson & Johnson exited a partnership on a Darzalex follow-up.
News AbbVie pays Gubra $350m upfront to enter obesity field AbbVie has joined the ranks of pharma groups trying to develop weight-loss drugs, licensing an amylin agonist from Gubra in a $2.2bn-plus deal.
News Kyorin partners Hyfe to develop DTx for chronic cough Kyorin Pharma has signed a deal with Hyfe to develop a digital therapeutic (DTx) for people with chronic cough and launch it in Japan.
News Lyfegen partners EVERSANA on pricing, access resource Lyfegen and EVERSANA have joined forces to help pharma companies navigate an increasingly complex global drug pricing and access environment.
News Latigo raises $150m for non-opioid painkiller push Latigo has tapped into investor interest in pain relief medicines with new, non-opioid mechanisms of action, raising $150 million in a Series B.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl